Oriola’s pro forma figures 2017 - 2018 based on new operating model
11.4.2019
Oriola Corporation Stock Exchange Release 11 April 2019 at 3:30 p.m.
Oriola’s pro forma figures 2017 - 2018 based on new operating model
On 18 September 2018, Oriola announced that Oriola’s Board of Directors has approved the company’s new operating model. Oriola’s business has been divided into three business areas operating in Finland and Sweden: Consumer, Pharma and Retail. These three business areas are also the Group’s new financial reporting segments according to IFRS 8. The changes in organisation took effect as of 1 January 2019.
The new business area structure is based on customer focus. Consumer offers products and services for health and wellbeing for consumers through Kronans Apotek, the third largest pharmacy chain in Sweden. Pharma provides tailored logistics, expert and advisory services to pharmaceutical companies, as well as a wide range of pharmaceutical products to pharmacies, hospital pharmacies and veterinarians. Retail provides a wide range of health and wellbeing products to pharmacies, veterinarians, private and public healthcare operators and retailers as well as dose dispensing, special licence medicines and pharmacy staffing services.
Oriola’s financial reporting will be aligned with the new operating model starting from January-March 2019 Interim report, to be published on 26 April 2019. The restated figures for the comparative periods are presented in the tables below.
Reporting segments, pro forma
| Invoicing | 2018 | 2018 | 2018 | 2018 | 2017 |
| EUR million | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 769.5 | 573.7 | 391.0 | 193.9 | 780.5 |
| Pharma | 2,697.1 | 1,972.7 | 1,322.3 | 639.0 | 2,502.2 |
| Retail | 431.2 | 323.8 | 224.2 | 113.5 | 403.5 |
| Invoicing between segments | -379.4 | -280.9 | -192.5 | -98.0 | -349.8 |
| Total | 3,518.4 | 2,589.2 | 1,745.0 | 848.3 | 3,336.3 |
| Net sales | 2018 | 2018 | 2018 | 2018 | 2017 |
| EUR million | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 751.9 | 561.1 | 382.3 | 189.5 | 762.0 |
| Pharma | 749.9 | 554.5 | 374.1 | 183.5 | 713.2 |
| Retail | 429.8 | 322.8 | 223.5 | 113.2 | 402.3 |
| Net sales between segments | -379.4 | -280.9 | -192.5 | -98.0 | -349.8 |
| Total | 1,552.2 | 1,157.5 | 787.5 | 388.1 | 1,527.7 |
| EBIT | 2018 | 2018 | 2018 | 2018 | 2017 |
| EUR million | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 17.7 | 14.6 | 9.8 | 3.8 | 25.2 |
| Pharma | 21.1 | 17.0 | 6.6 | 3.1 | 14.0 |
| Retail | 1.3 | 5.9 | 2.6 | 1.9 | 5.7 |
| Group administration and others | -18.1 | -7.6 | -5.5 | -3.2 | -7.1 |
| Total | 22.0 | 30.0 | 13.5 | 5.6 | 37.8 |
| Adjusted EBIT | 2018 | 2018 | 2018 | 2018 | 2017 |
| EUR million | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 18.8 | 15.8 | 9.9 | 4.0 | 25.2 |
| Pharma | 21.1 | 17.0 | 6.6 | 3.1 | 15.1 |
| Retail | 5.9 | 5.9 | 2.6 | 1.9 | 5.7 |
| Group administration and others | -8.9 | -7.0 | -5.0 | -2.7 | -6.1 |
| Total | 36.9 | 31.7 | 14.2 | 6.2 | 39.9 |
| Number of personnel | 2018 | 2018 | 2018 | 2018 | 2017 |
| at the end of the period | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 1,601 | 1,598 | 1,612 | 1,591 | 1,581 |
| Pharma | 507 | 506 | 497 | 493 | 502 |
| Retail | 530 | 517 | 584 | 544 | 491 |
| Group administration and others | 68 | 67 | 65 | 59 | 46 |
| Total | 2,706 | 2,688 | 2,758 | 2,687 | 2,619 |
| 2018 | 2018 | 2018 | 2018 | 2017 | |
| Average number of personnel | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 1,591 | 1,586 | 1,571 | 1,544 | 1,582 |
| Pharma | 506 | 505 | 499 | 504 | 494 |
| Retail | 540 | 546 | 548 | 545 | 564 |
| Group administration and others | 62 | 60 | 57 | 53 | 47 |
| Total | 2,699 | 2,697 | 2,675 | 2,646 | 2,686 |
| Quarterly invoicing | 2018 | 2018 | 2018 | 2018 | 2017 | 2017 | 2017 | 2017 |
| EUR million | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Consumer | 195.9 | 182.7 | 197.1 | 193.9 | 193.3 | 191.6 | 199.1 | 196.5 |
| Pharma | 724.4 | 650.4 | 683.3 | 639.0 | 661.4 | 620.5 | 631.2 | 589.1 |
| Retail | 107.4 | 99.6 | 110.7 | 113.5 | 109.0 | 96.0 | 102.0 | 96.5 |
| Invoicing between segments | -98.5 | -88.5 | -94.4 | -98.0 | -92.2 | -84.9 | -88.1 | -84.6 |
| Total | 929.1 | 844.2 | 896.7 | 848.3 | 871.6 | 823.1 | 844.2 | 797.5 |
| Quarterly net sales | 2018 | 2018 | 2018 | 2018 | 2017 | 2017 | 2017 | 2017 |
| EUR million | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Consumer | 190.8 | 178.8 | 192.8 | 189.5 | 188.7 | 187.2 | 194.2 | 191.9 |
| Pharma | 195.4 | 180.4 | 190.7 | 183.5 | 190.0 | 179.6 | 179.7 | 163.9 |
| Retail | 107.1 | 99.2 | 110.3 | 113.2 | 108.7 | 95.7 | 101.7 | 96.2 |
| Net sales between segments | -98.5 | -88.5 | -94.4 | -98.0 | -92.1 | -84.9 | -88.1 | -84.6 |
| Total | 394.7 | 369.9 | 399.4 | 388.1 | 395.2 | 377.6 | 387.5 | 367.4 |
| Quarterly EBIT | 2018 | 2018 | 2018 | 2018 | 2017 | 2017 | 2017 | 2017 |
| EUR million | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Consumer | 3.0 | 4.9 | 6.0 | 3.8 | 4.2 | 8.6 | 7.3 | 5.1 |
| Pharma | 4.1 | 10.5 | 3.5 | 3.1 | 0.3 | 1.8 | 6.0 | 5.9 |
| Retail | -4.6 | 3.2 | 0.8 | 1.9 | 1.6 | 1.5 | 1.2 | 1.4 |
| Group administration and others | -10.5 | -2.1 | -2.3 | -3.2 | -2.2 | -1.2 | -1.8 | -1.8 |
| Total | -8.0 | 16.5 | 7.9 | 5.6 | 3.9 | 10.7 | 12.7 | 10.5 |
| Quarterly adjusted EBIT | 2018 | 2018 | 2018 | 2018 | 2017 | 2017 | 2017 | 2017 |
| EUR million | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Consumer | 3.0 | 5.8 | 6.0 | 4.0 | 4.4 | 7.6 | 8.0 | 5.3 |
| Pharma | 4.1 | 10.5 | 3.5 | 3.1 | 1.5 | 1.8 | 6.0 | 5.9 |
| Retail | 0.0 | 3.2 | 0.8 | 1.9 | 1.6 | 1.5 | 1.2 | 1.4 |
| Group administration and others | -1.9 | -2.0 | -2.3 | -2.7 | -1.2 | -1.2 | -2.1 | -1.5 |
| Total | 5.2 | 17.5 | 7.9 | 6.2 | 6.2 | 9.7 | 13.0 | 11.0 |
| Quarterly investments | 2018 | 2018 | 2018 | 2018 | 2017 | 2017 | 2017 | 2017 |
| EUR million | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Consumer | 2.7 | 1.1 | 2.0 | 1.1 | 1.7 | 2.9 | 1.6 | 2.9 |
| Pharma | 1.9 | 1.6 | 3.0 | 2.6 | 3.1 | 4.9 | 3.2 | 2.0 |
| Retail | 0.9 | 0.4 | 0.3 | 0.3 | 2.3 | 2.6 | 2.6 | 5.5 |
| Group administration and others | 1.7 | 3.1 | 12.1 | 4.8 | 2.0 | 1.8 | 3.9 | 3.1 |
| Total | 7.2 | 6.2 | 17.4 | 8.8 | 9.1 | 12.2 | 11.3 | 13.5 |
| Assets | 2018 | 2018 | 2018 | 2018 | 2017 |
| EUR million | 31 Dec | 30 Sep | 30 Jun | 31 Mar | 31 Dec |
| Consumer | 378.0 | 396.9 | 397.5 | 408.4 | 424.1 |
| Pharma | 324.0 | 322.3 | 323.0 | 325.8 | 334.2 |
| Retail | 117.4 | 122.7 | 123.6 | 121.4 | 116.3 |
| Group administration and others | 108.3 | 87.3 | 74.7 | 71.0 | 47.8 |
| Total | 927.7 | 929.1 | 918.8 | 926.6 | 922.4 |
| Liabilities | 2018 | 2018 | 2018 | 2018 | 2017 |
| EUR million | 31 Dec | 30 Sep | 30 Jun | 31 Mar | 31 Dec |
| Consumer | 51.0 | 49.1 | 63.2 | 54.1 | 58.6 |
| Pharma | 508.1 | 494.7 | 499.1 | 488.8 | 460.8 |
| Retail | 51.6 | 56.3 | 56.3 | 69.0 | 74.3 |
| Group administration and others | 135.5 | 139.2 | 126.0 | 142.1 | 131.0 |
| Total | 746.2 | 739.3 | 744.6 | 754.0 | 724.7 |
| Depreciation, amortisation | 2018 | 2018 | 2018 | 2018 | 2017 |
| and impairments, EUR million | 1-12 | 1-9 | 1-6 | 1-3 | 1-12 |
| Consumer | 14.8 | 11.3 | 7.8 | 4.2 | 17.0 |
| Pharma | 4.8 | 3.4 | 2.1 | 1.0 | 3.9 |
| Retail | 4.0 | 3.0 | 1.9 | 1.0 | 4.5 |
| Group administration and others | 0.5 | 0.3 | 0.2 | 0.1 | 0.3 |
| Total | 24.1 | 18.1 | 12.0 | 6.3 | 25.7 |
Oriola Corporation
Helena Kukkonen
CFO
Further information:
Helena Kukkonen
CFO
Tel. +358 10 429 2112
Email: helena.kukkonen@oriola.com
Distribution:
Nasdaq Helsinki Ltd.
Key media
Released by:
Oriola Corporation
Corporate Communications
Orionintie 5
02200 Espoo
www.oriola.com